Welcome to our dedicated page for Ginkgo Bioworks Holdings SEC filings (Ticker: DNABW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Ginkgo Bioworks Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Ginkgo Bioworks Holdings's regulatory disclosures and financial reporting.
Ginkgo Bioworks Holdings, Inc. Chief Financial Officer Steven P. Coen reported RSU vesting and related share movements. On July 16, 2026, 1,486 restricted stock units converted into Class A Common Stock. On July 17, 2026, he sold 752 shares at $7.903 per share to cover tax withholding obligations through a non-discretionary sell-to-cover arrangement.
Ginkgo Bioworks Holdings, Inc. insider Steve Coen filed to sell Class A common stock under a planned transaction. The notice lists 752 Class A shares to be sold through Fidelity Brokerage Services on the NYSE and identifies the shares as originating from restricted stock vesting used as compensation. It also reports prior Class A stock sales over the last three months.
HENRY CHRISTIAN O reported acquisition or exercise transactions in this Form 4 filing.
Ginkgo Bioworks Holdings, Inc. director Henry Christian O reported receiving a grant of 25,000 restricted stock units. Each RSU represents a contingent right to receive one share of Class A common stock. The award vests on the earlier of June 11, 2027 or the day before the next annual meeting, if he continues serving as a non-employee director. Following this grant, his reported RSU holdings from this award total 25,000 units.
Ginkgo Bioworks Holdings, Inc. reported that director Ross Fubini received a grant of 25,000 Restricted Stock Units on June 11, 2026. Each RSU represents a contingent right to one share of Class A common stock, with no cash exercise price.
The RSUs vest on the earlier of June 11, 2027 or the day immediately before the next annual meeting after the grant date, subject to Fubini continuing to serve as a non-employee director through the vesting date. Following this award, his directly held RSUs from this grant total 25,000 units.
Kosuri Sri reported acquisition or exercise transactions in this Form 4 filing.
Ginkgo Bioworks Holdings, Inc. director Sri Kosuri received a grant of 25,000 restricted stock units on June 11, 2026 as equity compensation. Each RSU represents a contingent right to receive one share of the company’s Class A common stock. The RSUs will vest on the earlier of June 11, 2027 or the day immediately before the next annual meeting after the grant date, provided Kosuri continues to serve as a non-employee director through that vesting date. This is a stock-based award, not an open-market share purchase or sale.
SLOAN HARRY reported acquisition or exercise transactions in this Form 4 filing.
Ginkgo Bioworks Holdings, Inc. director Harry Sloan received a grant of 25,000 restricted stock units on June 11, 2026. Each RSU represents a right to receive one share of Class A common stock. The RSUs vest on the earlier of June 11, 2027 or the day before the next annual meeting, if he continues serving as a non-employee director.
Austin Che reported proposed sales of Class A shares under Form 144, listing multiple sale notifications through a Fidelity Brokerage Services LLC account. Reported sale entries include 2,200 shares on 03/11/2026 for $13,882 and 40,893 shares on 04/13/2026 for $262,291.79, plus additional smaller dated entries.
Ginkgo Bioworks Holdings insider Steven P. Coen reported routine equity compensation activity involving restricted stock units and a related tax sale. On May 21, 2026, he exercised awards covering a total of 743 shares of Class A Common Stock at a conversion price of $0.00 per share, increasing his direct holdings.
On May 22, 2026, 307 shares of Class A Common Stock were sold at $8.334 per share to cover tax withholding obligations tied to the vesting of restricted stock and/or RSUs, as allowed under the company’s equity incentive plans. The footnotes state these "sell to cover" sales are not discretionary trades by the reporting person. After these transactions, Coen directly held 50,704 shares of Class A Common Stock.
The filing reports a proposed sale of 307 Class A shares tied to a Restricted Stock Vesting event with an issuer designation and a trade date of 05/21/2026. The excerpt also lists prior dispositions by Steve Coen: 708 shares on 03/16/2026, 33,171 shares on 04/13/2026, and 324 shares on 04/17/2026.
Ginkgo Bioworks Holdings, Inc. ownership disclosure: Viking Global Investors and affiliated entities report shared beneficial ownership of 3,577,128 shares of Class A Common Stock. The filing amends prior reports to remove David C. Ott as a reporting person effective March 31, 2026.
The filing states those 3,577,128 shares represent 7.1% of Class A Common Stock based on 50,254,065 shares outstanding as of March 31, 2026. The stake includes 2,900,025 directly held shares and 677,103 shares subject to forfeiture if price targets are not met.